What are the cardiovascular risks associated with febuxostat therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cardiovascular Risk with Febuxostat

For patients with gout and pre-existing cardiovascular disease, febuxostat carries a conditional recommendation to switch to alternative urate-lowering therapy (preferably allopurinol) due to concerns about increased cardiovascular mortality, though the absolute risk remains uncertain and requires shared decision-making. 1

Key Evidence on CV Risk

The cardiovascular safety profile of febuxostat is complex and somewhat contradictory:

The CARES Trial Findings

The FDA-mandated CARES trial showed no difference in the primary composite cardiovascular endpoint between febuxostat and allopurinol. However, febuxostat was associated with:

  • Higher cardiovascular-related death compared to allopurinol
  • Higher all-cause mortality (driven by CV deaths)
  • No difference in nonfatal MI, nonfatal stroke, or urgent revascularization

Critical limitations include a high dropout rate with most deaths occurring after discontinuation of therapy, making interpretation difficult. Importantly, there was no untreated control group, so the absolute cardiovascular risk attributable to febuxostat remains unknown. 1

Conflicting Observational Data

  • One large observational study (not selected for CVD) showed no increased risk of CVD or all-cause mortality with febuxostat versus allopurinol when controlling for confounding 1
  • Another managed care database study showed lower risk of major CV events with febuxostat, though confounding may not have been adequately addressed 1
  • Recent 2026 real-world data from US electronic health records showed comparable MACE risk (HR 1.027) but modestly increased all-cause mortality (HR 1.125) in CVD patients 2

Time-Varying Risk Pattern

The most recent 2026 meta-analysis reveals a time-dependent cardiovascular risk profile:

  • 0-12 months: Protective effect (HR 0.89 for CV risk, HR 0.70 for mortality)
  • 12-24 months: Significant protection (HR 0.58 for CV risk, HR 0.39 for mortality)
  • 24-48 months: Attenuated benefit (HR 0.86 for CV risk, HR 0.75 for mortality)
  • >48 months: No difference (HR 1.09 for CV risk, HR 1.02 for mortality) 3

Clinical Recommendations

First-Line Therapy

Allopurinol remains the strongly recommended first-line agent for all patients with gout, including those with cardiovascular disease, based on efficacy, tolerability, safety, and lower cost. 1

When Febuxostat is Considered

If febuxostat is being used in a patient with:

Pre-existing CVD or new CVD event: The 2020 ACR guideline conditionally recommends switching to an alternative oral urate-lowering agent (preferably allopurinol) if available and consistent with other clinical factors. 1

High-risk populations requiring extra caution:

  • Patients with diabetes mellitus and chronic kidney disease show higher risks with febuxostat: increased all-cause hospitalization (HR 1.33), heart failure hospitalization (HR 1.62), and CV intervention hospitalization (HR 1.51) 4
  • Age, BMI, and prior hypertension are independent risk factors for CV events in febuxostat-treated patients 5

Shared Decision-Making is Essential

The ACR guideline emphasizes that providers and patients must engage in shared decision-making when considering febuxostat for high-CV-risk patients. Patient panel input indicated willingness to accept "some" incremental CV risk if gout is adequately controlled. 1

Common Pitfalls to Avoid

  1. Don't assume equivalence: While some meta-analyses show no significant MACE difference 6, the mortality signal and time-varying effects warrant caution in CVD patients

  2. Don't ignore the time course: Early protective effects may give false reassurance; risk appears to increase after 2-4 years of therapy 3

  3. Don't use febuxostat as first-line in CVD patients: Allopurinol should be tried first with appropriate dose titration (starting ≤100 mg/day, lower in CKD) 1

  4. Don't continue febuxostat without reassessment: If a patient on febuxostat develops new CVD or has worsening CVD, strongly consider switching to allopurinol 1

Bottom Line Algorithm

For patients with gout and cardiovascular disease:

  1. Start with allopurinol (low dose with titration)
  2. If allopurinol fails or causes hypersensitivity, consider febuxostat only after thorough discussion of CV risks
  3. If already on febuxostat and CVD develops or worsens → switch to alternative therapy
  4. Monitor closely if continuing febuxostat, especially beyond 2 years of therapy

References

4
Research

Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease.

Medical science monitor : international medical journal of experimental and clinical research, 2024

Related Questions

In gout management, which urate‑lowering therapy—allopurinol or febuxostat—is superior for achieving target serum urate levels?
In adult gout patients, when should allopurinol be used instead of febuxostat, and when is febuxostat preferred, considering renal function (estimated glomerular filtration rate), hypersensitivity, HLA‑B*58:01 allele status, and recent major cardiovascular events?
Can febuxostat be discontinued abruptly?
Can febuxostat be used to treat gout?
When should urate‑lowering therapy with allopurinol or febuxostat be restarted after an acute gout flare?
What systemic medication is recommended for psoriasis in a patient with elevated liver function tests (elevated AST and ALT)?
In a patient with atrial fibrillation on chronic warfarin and a CHA₂DS₂‑VASc score of 2 who is scheduled for a diagnostic coronary angiogram, how should the anticoagulation be managed and is bridging with low‑molecular‑weight heparin required?
For an adult with Restless Legs Syndrome focused on nighttime sleep, is gabapentin superior to pregabalin in terms of sedation?
What ICD‑10 diagnosis code should be used for a pleural effusion when a chest‑tube thoracostomy is placed?
What is the recommended initial isotonic crystalloid (normal saline or lactated Ringer's) dose for an adult without contraindications presenting with sepsis, hypovolemic shock, or major trauma?
What evidence supports the use of ceramides in skin care?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.